Navigation Links
Slices of living brain tissue are helping scientists identify new stroke therapies
Date:1/21/2009

AUGUSTA, Ga. Slices of living human brain tissue are helping scientists learn which drugs can block the waves of death that engulf and engorge brain cells following a stroke.

It's called anoxic depolarization and it primarily results from the brain getting insufficient blood and oxygen after a stroke, says Dr. Sergei Kirov, neuroscientist in the Medical College of Georgia Schools of Medicine and Graduate Studies.

The brain uses about 20 percent of the body's total energy and about half of that is needed to run the pump that maintains healthy levels of sodium and potassium in and around brain cells. A stroke takes away the pump's fuel, called ATP, so neurons and supportive astroglial cells quickly become bloated and dysfunctional. Cells die if the pumps don't start working soon, Dr. Kirov says.

Resulting waves are responsible for much of the immediate brain cell death in the core of a stroke. Milder waves may continue to pound contiguous areas for hours or days, potentially increasing stroke size and damage. In this area called the penumbra, cells get a little more oxygen so there is the potential for recovery if the waves can be silenced, he says.

Dr. Kirov has been examining whether several drugs can stop the pounding of the penumbra in an animal model and has completed a small pilot study in human tissue. The scientist, who directs MCG's Human Brain Laboratory, recently received a second grant from the National Institute of Neurological Disorders and Stroke to focus on the drugs' potential in human tissue. "We only have one approved drug therapy for stroke and new approaches are needed to improve treatment for the third leading cause of death in western countries," he says. He and others believe a focus on human tissue will better identify therapies that have real clinical merit.

A special report in the Nov. 29, 2007 issue of Stroke noted the failure in humans of numerous stroke therapies that looked promising in animal studies and outlined a new road map that includes better proof of efficacy in animal models as well as studies in human brain tissue focusing on the penumbra.

Dr. Kirov agrees. "Human brain slices as a model system can provide a missing link between animal models and patients and offer a unique chance to identify and study potentially useful therapeutics."

He is getting live images of glowing human neurons or astroglial cells to look first at the simulated stroke and then at what protection different drugs provide. The tissue is removed primarily during epilepsy surgery at MCGHealth Medical Center and Children's Medical Center. He replicates a stroke in the tissue by withholding oxygen and glucose then measures whether drugs can block anoxic depolarization.

There is plenty of living proof that cells can recover if the waves are short term: that's essentially what happens in migraines. "Some people describe these moving through their visual field: a wave silencing, but not killing, the neurons," Dr. Kirov says. Precisely what starts the wave remains an unanswered question. But he thinks he may be able to help delay or prevent the destructive electrical activity they bring without depressing usual central nervous system action.

He's testing dibucaine, a local anesthetic known to impact ion channels, which regulate the flow of negatively and positively charged molecules in and out of cells. Positively charged potassium, for example, normally leaks out through ion channels. With anoxic depolarization, there's too much sodium and too little potassium inside cells. He's also studying two sigma receptor ligands, dextromethorphan and carbetapentane. Sigma receptors are ubiquitous in the body, but little is known about their role and what naturally activates them. Recent research suggests sigma receptors help protect cells from stress by ensuring an adequate level of the properly folded proteins they need for normal function. MCG Retinal Biologist Sylvia Smith and others have shown that sigma receptors are located within the endoplasmic reticulum of cells, which controls protein synthesis and regulates calcium levels. When needed, the receptors appear to chaperone these proteins to the cell powerhouse, or mitochondria. In his studies, Dr. Kirov is testing to see whether these sigma receptor ligands inhibit anoxic depolarization in humans to forecast translational success.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert  

Related medicine news :

1. AT&T Mobility and Brookdale Senior Living Host First Cell Phones for Seniors Public Service Event in New York City
2. Senior Living Provider Invites Residents to Dream. Dare. Discover!
3. New Year starts with focus on healthy living
4. SantaFe Senior Living Announces Leadership Transition
5. Moshi Names Independent Living Aids Exclusive Distributor in Blindness and Visual Impairment Field
6. Finding Grace on a Less Traveled Road: A Cancer Doctor Reflects on Living and Dying
7. AdCare Health Systems, Inc. Acquires Remaining Ownership in Van Wert Assisted Living Property
8. Southern AIDS Living Quilt Raises Awareness in Washington, D.C.
9. In-House Hospice Offers Help to Those Living With Grief During Holiday Time
10. Courion Helps Reduce Costs at Nations Largest Operator of Senior Living Communities
11. Southern AIDS Living Quilt Coming to Washington, D.C.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Slices of living brain tissue are helping scientists identify new stroke therapies
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ODH, Inc.™ ... Care Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s ... PerformCARE to use behavioral health analytics to improve Medicaid population health management. , ODH ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... newly designed TaskMate Go. Core benefits and advantages built into the home office ... stylish, functional look and feel. Ability to gain the benefits embedded in the ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis ... University of Pittsburgh points to eight genes that may explain why susceptibility to one ... the results of a study published today in the journal npj Schizophrenia. , ...
(Date:2/24/2017)... ... 2017 , ... With millions of Americans and people worldwide ... all are aware of our options and are empowered with strength and information ... of its newest edition of "Vision and Hearing" in USA Today, that will ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University Institute for Palliative ... in or interested in palliative care education and research. The Symposium, “Innovate. Investigate. ... County San Diego on Sept. 28 and 29, 2017, on the campus of California ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... YORK , Feb. 23, 2017  This report ... Thousand by the following Products: Intermediates, ... in the report include Pharmaceuticals, and Agrochemicals. The report ... Japan , Europe , and ... for the period 2015 through 2022. Also, a six-year ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
(Date:2/23/2017)... -- Genesis Healthcare Services has merged with Hospice Cloud, a ... Bill Monast , President and CEO of Hospice Cloud ... , executives with Home Health Depot, Inc., the parent ... This acquisition helps Hospice Cloud maintain its position as ... equipment (DME) solutions for the hospice industry. Nathan ...
Breaking Medicine Technology: